Anti-HER2 antibody-drug conjugate effective for first-line therapy in advanced breast
 

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

More...